Informações:
Falhas:
ID
23993
Descrição
Comparison of Nutritional Products for People With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00520065
Link
https://clinicaltrials.gov/show/NCT00520065
Palavras-chave
Versões (1)
- 20/07/2017 20/07/2017 -
Transferido a
20 de julho de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Type 2 Diabetes Mellitus NCT00520065
Eligibility Type 2 Diabetes Mellitus NCT00520065
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes Mellitus NCT00520065
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
signed and dated informed consent form
boolean
C0021430 (UMLS CUI [1])
ID.2
Item
type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
ID.3
Item
18 to 75 years of age
boolean
C0001779 (UMLS CUI [1])
ID.4
Item
male or non-pregnant, non-lactating female, at least 6 weeks postpartum
boolean
C0079399 (UMLS CUI [1,1])
C0032961 (UMLS CUI [1,2])
C1180275 (UMLS CUI [1,3])
C0032961 (UMLS CUI [1,2])
C1180275 (UMLS CUI [1,3])
ID.5
Item
if female is of childbearing potential, is practicing birth control
boolean
C0700589 (UMLS CUI [1])
ID.6
Item
bmi greater than or equal to 18.5 kg/m2 and less than 40.0 kg/m2
boolean
C1305855 (UMLS CUI [1])
ID.7
Item
medications, such as antihyperglycemic or thyroid medications or hormone therapy, have been maintained at a constant dosage for at least two months prior to screening visit
boolean
C0205360 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])
ID.8
Item
uses exogenous insulin for glucose control
boolean
C0557978 (UMLS CUI [1])
ID.9
Item
type 1 diabetes
boolean
C0011854 (UMLS CUI [1])
ID.10
Item
history of diabetic ketoacidosis
boolean
C0011880 (UMLS CUI [1])
ID.11
Item
current infection; has received corticosteroid treatment in the last 3 months, or has had surgery or received antibiotics in the last 3 weeks
boolean
C3714514 (UMLS CUI [1,1])
C3540704 (UMLS CUI [1,2])
C0543467 (UMLS CUI [1,3])
C0149783 (UMLS CUI [1,4])
C3540704 (UMLS CUI [1,2])
C0543467 (UMLS CUI [1,3])
C0149783 (UMLS CUI [1,4])
ID.12
Item
active malignancy
boolean
C0006826 (UMLS CUI [1])
ID.13
Item
significant cardiovascular event less than 12 weeks prior to study entry
boolean
C1320716 (UMLS CUI [1])
ID.14
Item
end stage organ failure or is status post organ transplant
boolean
C0561718 (UMLS CUI [1,1])
C0029216 (UMLS CUI [1,2])
C0029216 (UMLS CUI [1,2])
ID.15
Item
has an active metabolic, hepatic, or gastrointestinal disease that may interfere with nutrient absorption, distribution, metabolism, or excretion excluding diabetes
boolean
C0025519 (UMLS CUI [1,1])
C1961155 (UMLS CUI [1,2])
C0520511 (UMLS CUI [1,3])
C1961155 (UMLS CUI [1,2])
C0520511 (UMLS CUI [1,3])
ID.16
Item
chronic, contagious, infectious disease, such as active tuberculosis, hepatitis b or c, or hiv
boolean
C0008679 (UMLS CUI [1,1])
C0009450 (UMLS CUI [1,2])
C0009450 (UMLS CUI [1,2])
ID.17
Item
taking any herbals, dietary supplements or medications, other than antihyperglycemic medications during the past four weeks that could profoundly affect blood glucose
boolean
C0013227 (UMLS CUI [1])
ID.18
Item
fainted or experienced other adverse reactions in response to blood collection prior to this study
boolean
C0559546 (UMLS CUI [1])
ID.19
Item
has clotting or bleeding disorders
boolean
C0005779 (UMLS CUI [1])
ID.20
Item
allergic or intolerant to any ingredient found in the study products
boolean
C0020517 (UMLS CUI [1])
ID.21
Item
participant in a concomitant trial that conflicts with this study
boolean
C0008976 (UMLS CUI [1])